A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
To reduce the toxicity of cisplatin N-(2,3,4,5,6-pentahydroxylhex-1-yl)-N-dithiocarbamate-L-isoleucine disodium (GID) based therapeutic alliance is investigated. For the proliferation of HepG 2 , Hela, MES-SA, HL 60 and H1299 cells, 27μM of GID based therapeutic alliance gave comparable inhibition to cisplatin alone. For implanted tumor proliferation in mice, 1.667μmol/kg of GID based therapeutic alliance gave higher inhibition than cisplatin alone. For cisplatin receiving mice, thisdoi:10.2174/1874340400802010001 fatcat:gjhkungy2fe2vaflfi4ivhcsce